{"transactions":[{"id":2003008,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-21T18:53:33.000Z","date":"2023-02-17","kind":"grant","acquired":true,"shares":77000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":77000,"derivative":{"exercise_price":11.34,"expiration_date":"2033-02-16","underlying":"Common Stock","underlying_shares":77000},"source":{"system":"sec-edgar","filing":"0000899243-23-005731","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1362054/000089924323005731/doc4.xml","form_type":"4"}},{"id":2003007,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-02-21T18:53:33.000Z","date":"2023-02-17","kind":"grant","acquired":true,"shares":38500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":76000,"source":{"system":"sec-edgar","filing":"0000899243-23-005731","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362054/000089924323005731/doc4.xml","form_type":"4"}},{"id":2394077,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-15T16:48:05.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the option vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":75000,"derivative":{"exercise_price":13.6,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-22-006419","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1362054/000089924322006419/doc4.xml","form_type":"4"}},{"id":2394076,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-02-15T16:48:05.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares underlying the restricted stock unit vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":37500,"source":{"system":"sec-edgar","filing":"0000899243-22-006419","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362054/000089924322006419/doc4.xml","form_type":"4"}},{"id":2574513,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-09T16:15:23.000Z","date":"2021-09-08","kind":"exercise","acquired":false,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares vested on September 1, 2019, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":240114,"derivative":{"exercise_price":4.3,"expiration_date":"2030-10-28","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-21-035415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1362054/000089924321035415/doc4.xml","form_type":"4"}},{"id":2574512,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-09-09T16:15:23.000Z","date":"2021-09-08","kind":"sale","acquired":false,"shares":11000,"price":28.45,"value":312950.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 30, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-035415","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1362054/000089924321035415/doc4.xml","form_type":"4"}},{"id":2574511,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-09-09T16:15:23.000Z","date":"2021-09-08","kind":"exercise","acquired":true,"shares":11000,"price":4.3,"value":47300.0,"ownership":{"direct":true},"balance_after":11000,"source":{"system":"sec-edgar","filing":"0000899243-21-035415","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362054/000089924321035415/doc4.xml","form_type":"4"}},{"id":2589338,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-26T19:11:47.000Z","date":"2021-08-10","kind":"exercise","acquired":false,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares vested on September 1, 2019, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":251114,"derivative":{"exercise_price":4.3,"expiration_date":"2030-10-28","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-21-034306","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1362054/000089924321034306/doc4.xml","form_type":"4"}},{"id":2589337,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-08-26T19:11:47.000Z","date":"2021-08-10","kind":"sale","acquired":false,"shares":11000,"price":27,"value":297000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 30, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-034306","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1362054/000089924321034306/doc4.xml","form_type":"4"}},{"id":2589336,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-08-26T19:11:47.000Z","date":"2021-08-10","kind":"exercise","acquired":true,"shares":11000,"price":4.3,"value":47300.0,"ownership":{"direct":true},"balance_after":11000,"source":{"system":"sec-edgar","filing":"0000899243-21-034306","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362054/000089924321034306/doc4.xml","form_type":"4"}},{"id":2910701,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-11T17:37:23.000Z","date":"2021-01-07","kind":"grant","acquired":true,"shares":286665,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option represents a right to purchase a total of 286,665 shares of the Issuer's Common Stock, 25% of which will become fully vested and exercisable on January 7, 2022, with the remaining shares vesting in equal monthly installments over the following three years (36 months), subject to the reporting person's continued employment with the Issuer."}],"balance_after":286665,"derivative":{"exercise_price":21,"expiration_date":"2031-01-06","underlying":"Common Stock","underlying_shares":286665},"source":{"system":"sec-edgar","filing":"0000899243-21-001369","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362054/000089924321001369/doc4.xml","form_type":"4"}},{"id":2948777,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-11T06:16:43.000Z","date":"2020-12-10","kind":"grant","acquired":true,"shares":12100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest and become exercisable on January 1, 2022, with the remainder vesting in twenty-four (24) equal monthly installments thereafter."}],"balance_after":12100,"derivative":{"exercise_price":31.83,"expiration_date":"2030-12-09","underlying":"Common Stock","underlying_shares":12100},"source":{"system":"sec-edgar","filing":"0000899243-20-033475","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924320033475/doc4.xml","form_type":"4"}},{"id":3128803,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2020-06-01T21:38:57.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":2584,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the last day of each calendar quarter following the grant date of May 28, 2020 (on June 30, 2020, September 30, 2020, December 31, 2020, and March 31, 2021), subject to the continuous service of the Reporting Person on each vesting date."}],"balance_after":2584,"derivative":{"exercise_price":20.59,"expiration_date":"2030-05-27","underlying":"Common Stock","underlying_shares":2584},"source":{"system":"sec-edgar","filing":"0001209191-20-033318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1362054/000120919120033318/doc4.xml","form_type":"4"}},{"id":3128802,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2020-06-01T21:38:57.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":10167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will fully vest and become exercisable on May 28, 2021, subject to the continuous service of the Reporting Person with the Issuer on such date."}],"balance_after":10167,"derivative":{"exercise_price":20.59,"expiration_date":"2030-05-27","underlying":"Common Stock","underlying_shares":10167},"source":{"system":"sec-edgar","filing":"0001209191-20-033318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362054/000120919120033318/doc4.xml","form_type":"4"}},{"id":3329581,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-30T17:32:07.000Z","date":"2019-12-27","kind":"sale","acquired":false,"shares":1400,"price":18.069,"value":25296.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $17.57 to $18.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares indirectly held by APAK Solutions GmbH, of which the Reporting Person has sole voting and investment power over these shares."}],"balance_after":262136,"source":{"system":"sec-edgar","filing":"0001209191-19-062169","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1362054/000120919119062169/doc4.xml","form_type":"4"}},{"id":3329580,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-30T17:32:07.000Z","date":"2019-12-27","kind":"sale","acquired":false,"shares":10417,"price":16.9014,"value":176061.8838,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $16.51 to $17.45 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares indirectly held by APAK Solutions GmbH, of which the Reporting Person has sole voting and investment power over these shares."}],"balance_after":263536,"source":{"system":"sec-edgar","filing":"0001209191-19-062169","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1362054/000120919119062169/doc4.xml","form_type":"4"}},{"id":3329579,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-30T17:32:07.000Z","date":"2019-12-27","kind":"sale","acquired":false,"shares":75562,"price":15.8138,"value":1194922.3556,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $15.51 to $16.30 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares indirectly held by APAK Solutions GmbH, of which the Reporting Person has sole voting and investment power over these shares."}],"balance_after":273953,"source":{"system":"sec-edgar","filing":"0001209191-19-062169","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362054/000120919119062169/doc4.xml","form_type":"4"}},{"id":3331393,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-26T17:30:37.000Z","date":"2019-12-23","kind":"sale","acquired":false,"shares":84907,"price":15.44,"value":1310964.08,"ownership":{"direct":false,"nature":"By APAK Solutions GmbH"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"$15.44 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.01 to $16.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by APAK Solutions GmbH. The Reporting Person is managing director of APAK Solutions GmbH. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":350786,"source":{"system":"sec-edgar","filing":"0000899243-19-030063","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319030063/doc4.xml","form_type":"4"}},{"id":3331392,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-26T17:30:37.000Z","date":"2019-12-20","kind":"sale","acquired":false,"shares":32022,"price":15.16,"value":485453.52,"ownership":{"direct":false,"nature":"By APAK Solutions GmbH"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"$15.16 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by APAK Solutions GmbH. The Reporting Person is managing director of APAK Solutions GmbH. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":435693,"source":{"system":"sec-edgar","filing":"0000899243-19-030063","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319030063/doc4.xml","form_type":"4"}},{"id":3500121,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2019-06-05T17:14:54.000Z","date":"2019-06-03","kind":"grant","acquired":true,"shares":10167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will fully vest and become exercisable on June 3, 2020, subject to the continuous service of the Reporting Person with the Issuer on such date."}],"balance_after":10167,"derivative":{"exercise_price":11.84,"expiration_date":"2029-06-02","underlying":"Common Stock","underlying_shares":10167},"source":{"system":"sec-edgar","filing":"0001209191-19-034828","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362054/000120919119034828/doc4.xml","form_type":"4"}},{"id":3556745,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-12T16:10:25.000Z","date":"2019-04-11","kind":"grant","acquired":true,"shares":59850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on January 1, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter."}],"balance_after":59850,"derivative":{"exercise_price":16.11,"expiration_date":"2029-04-10","underlying":"Common Stock","underlying_shares":59850},"source":{"system":"sec-edgar","filing":"0001750019-19-000027","document":"wf-form4_155509981067242.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000175001919000027/wf-form4_155509981067242.xml","form_type":"4"}},{"id":3573871,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":116660,"kind":"person","name":"Baeuerle Patrick","position":1,"cik":"0001362054","reported_name":"Baeuerle Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2019-03-29T16:12:48.000Z","date":"2019-02-07","kind":"grant","acquired":true,"shares":3829,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the last day of each calendar quarter following the grant date of February 7, 2019 (on March 31, 2019, June 30, 2019, September 30, 2019, and December 31, 2019), subject to the continuous service of the Reporting Person on each vesting date."}],"balance_after":3829,"derivative":{"exercise_price":14,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":3829},"source":{"system":"sec-edgar","filing":"0001209191-19-021729","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362054/000120919119021729/doc4.xml","form_type":"4"}}]}